Skip to Main Content

Almost five years after debuting his first biotech company, noted writer and oncologist Siddhartha Mukherjee has officially unveiled his second: Myeloid Therapeutics. The new company, based in Cambridge, Mass., launched Wednesday with a $50 million Series A.

Myeloid is putting a twist on cell cancer therapies like CAR-T that are already successful in blood cancers and using a similar idea to take on conditions like glioblastoma, which form solid tumors. It will use so-called myeloid cells, the collective term for some kinds of blood and immune cells, to trigger the rest of a person’s immune system.


“We and others have found that cancer cells form a kind of shell,” Mukherjee said in an interview. “You can’t penetrate the shell. So we began to wonder, ‘Well, what cells penetrate the shells normally?’”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!